Summary:
Click image to enlarge
TALK WITH YOUR DOCTOR TODAY!
Some Important Facts to Know About Alzheimer’s Disease
- Alzheimer’s disease was initially identified more than 100 years ago. However, research into its symptoms, causes, risk factors, and treatment has gained momentum only in the last 30 years.
- While research has provided a lot of information about the disease, the exact cause of Alzheimer’s is still unknown.
- One in nine people over the age of 65 have Alzheimer’s. For up to 5% of the more than 5 million Americans with Alzheimer’s, the onset of the disease will occur in their 40s or 50s.
- In 2013, unpaid caregivers, typically immediate family members, gave an estimated 17.7 billion hours of their time to care for loved ones with Alzheimer’s.
- Not only are women more likely to have Alzheimer’s, they are also more likely to be caregivers of those with Alzheimer’s.
What is the STEADFAST Study?
The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease.
There will be two groups of people in the study:
- One group will receive azeliragon (5 mg daily taken orally) in addition to their regular medication(s).
- One group will receive a placebo (a substance with no active ingredients) in addition to their regular medication(s).
Why should I consider participating in the STEADFAST Study?
- By participating in this study, you can learn more about the treatment of Alzheimer’s disease.
- You may receive the study medication, azeliragon, which may be effective at slowing the progression of Alzheimer’s disease
- Participating in studies helps advance research, which may help the future treatment of this currently incurable disease.
Do I qualify for this study?
You may quality for this study if you:
- Have been diagnosed with mild Alzheimer’s disease.
- Are at least 50 years of age.
- Have been taking one or more of the following medications for at least 3 months: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon®.
What will I need to do for the STEADFAST Study?
- The study will last approximately 23 months and involves about 9 visits to the doctor’s office, with most visits occurring every 3 months.
- You must attend all study visits with your caregiver.
- You will need to take your study medication every day, as instructed.
- You must continue to take your regular Alzheimer’s disease medication as you normally do.
- You will need to tell the study doctor of any changes to your health or medications while in the study.